Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel

Trastuzumab, pertuzumab, and docetaxel (THP) have represented the standard first-line treatment for HER2-positive metastatic breast cancer (MBC) for over a decade, following the pivotal CLEOPATRA trial. However, interim results from the DESTINY-Breast09 trial suggest that trastuzumab deruxtecan (T-D...

Full description

Bibliographic Details
Authors: Kubeczko, Marcin, d'Amico, Andrea, Chrabanski, Olgierd, Handkiewicz-Junak, Daria, Polakiewicz-Gilowsk, Anna, Swiderska, Katarzyna, Mianowska-Malec, Marta, Lesniak, Aleksandra, Lanoszka, Barbarba, Lisovska, Natalya, Borys, Damian, Pycinski, Bartlomiej, Ewa Chmielik, Slawomir Blamek, Prat Aparicio, Aleix, Michal Jarzab
Format: article
Status:Published version
Publication Date:2025
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/225966
Online Access:https://hdl.handle.net/2445/225966
Access Level:Open access
Keyword:Càncer de mama
Marcadors bioquímics
Metàstasi
Breast cancer
Biochemical markers
Metastasis
Description
Summary:Trastuzumab, pertuzumab, and docetaxel (THP) have represented the standard first-line treatment for HER2-positive metastatic breast cancer (MBC) for over a decade, following the pivotal CLEOPATRA trial. However, interim results from the DESTINY-Breast09 trial suggest that trastuzumab deruxtecan (T-DXd) may soon replace THP as the new first-line standard. Recent developments in treatment have raised new questions about how best to match therapy intensity with individual patient profiles. FDG PET/CT, routinely used for metabolic imaging, might help by identifying patients with differing prognoses based on baseline tumor activity. We investigated the prognostic relevance of baseline FDG PET/CT and its association with treatment outcomes in HER2-positive MBC patients receiving first-line THP.

Similar Items